Oncopeptides AB (SE0009414576)

Overview

Onconetix, Inc. is a pioneering entity in the biotechnology and pharmaceutical fields, committed to innovating and delivering transformative therapies globally. Initially established as Blue Water Biotech, Inc., the company transitioned to its current name, Onconetix, Inc., in December 2023. Since its inception in 2018, Onconetix has made significant strides in addressing complex health challenges. It has positioned itself at the forefront of the industry with the development of groundbreaking pharmaceuticals. The company's headquarters are situated in Cincinnati, Ohio, marking its presence as a significant player in the biotech and pharmaceutical landscape.

Products and Services

• Entadfi

Entadfi represents a landmark advancement in the treatment of benign prostatic hyperplasia (BPH). It is a once-daily oral pill that ingeniously combines finasteride and tadalafil. This FDA-approved medication showcases Onconetix, Inc.'s capability to blend existing drugs to create innovative treatments that significantly improve patient outcomes and convenience.

• Streptococcus Pneumoniae Vaccine Candidate

Addressing a common cause of morbidity among children and the elderly, Onconetix, Inc. is in the process of developing a vaccine aimed at preventing infectious middle ear infections in children and pneumonia in the elderly. The focus on this streptococcus pneumoniae vaccine candidate demonstrates the company's dedication to tackling infections that have widespread health implications across different age groups.

• Universal Flu Vaccine

The endeavor to create a universal flu vaccine illustrates Onconetix, Inc.'s ambition to revolutionize the way influenza is prevented. By aiming to provide protection from all virulent strains, this vaccine holds the potential to significantly reduce the incidence and severity of flu outbreaks globally, showing promise towards better public health outcomes.

• Norovirus S&P Nanoparticle Versatile Virus-like Particle Vaccine Platform

With an exclusive licensing agreement with Cincinnati Children's, Onconetix, Inc. is setting the stage for the development of vaccines against multiple infectious diseases using a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform. This groundbreaking approach not only targets the development of vaccines for diseases like Marburg and monkeypox but also opens the door for the advancement of vaccines against a wider array of infectious diseases. This initiative highlights the company's innovative capabilities and its commitment to addressing global health threats through pioneering vaccine technology.